HELICOBACTER PYLORI (HP) INFECTION IN OBESE PATIENTS UNDERGOING ROUXEN- Y GASTRIC BYPASS; EFFICACY OF TWO DIFFERENT TREATMENT REGIMENS IN HP ERADICATION.
BACKGROUND
the ultimate cause for the increased incidence of gastric ulcer following Roux-en-Y gastric bypass (RYGB) remains unclear. Treatment of HP infection is recommended before surgery in countries with high prevalence such as Spain in other to diminish the risk. However, the current regimens used might not be adequate in view of the high failure rate for HP eradication.


METHODS
we reviewed 243 patients retrospectively undergoing RYGB and found 111 patients (45%) with HP infection. Therefore, we compared the eradication rate between 2 different regimens.


RESULTS
70 patients received OCA(Omeprazole:20 mg/12h, Clarithromycin 500 mg/12h and Amoxicillin 1 gram/12h for 10 days) while 41 patients received OLA (Omeprazole 20 mg/12 hours, Levofloxacin 500 mg/12hours and Amoxicillin 1 gram/12h for 10 days) for HP eradication. In 56/70 (80%) patients receiving OCA therapy HP was eradicated compared to 37/41 (91%) receiving OLA as first line therapy (p = 0.283). When used as second line therapy, in 13/14 (92%) patients receiving OLA HP was eradicated.


CONCLUSIONS
clarithromycin resistance remains a matter of concern in this population while OLA seems to be a good alternative therapy for HP eradication, especially when OCA regimen fails.
Department of Endocrinology and Nutrition. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid.. cuestamartintutor@gmail.com.
Martín
M
Cuesta Hernández
Department of Endocrinology and Nutrition. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid.. marubioh@gmail.com.
Celia
C
Pérez Peña
Department of Endocrinology and Nutrition. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid.. marubioh@gmail.com.
Pilar
P
Matía Martín
Department of Endocrinology and Nutrition. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid.. marubioh@gmail.com.
Lucio
L
Cabrerizo García
Department of Endocrinology and Nutrition. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid.. marubioh@gmail.com.
Natalia
N
Pérez-Ferre
Department of Surgery. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid (Spain).. marubioh@gmail.com.
Andrés
A
Sánchez-Pernaute
Department of Surgery. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid (Spain).. marubioh@gmail.com.
Antonio
A
Torres García
Department of Endocrinology and Nutrition. Hospital Clínico San Carlos. Instituto de Investigación Sanitaria San Carlos (IdISSC). Facultad de Medicina. Universidad Complutense, Madrid.. marubioh@gmail.com.
Miguel Ángel
MÁ
Rubio Herrera
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000907:Antibodies, Bacterial / Q000276:immunology; D015992:Body Mass Index; D004359:Drug Therapy, Combination; D005260:Female; D015390:Gastric Bypass / Q000379:methods; D016481:Helicobacter Infections / Q000150:complications* / Q000175:diagnosis / Q000628:therapy*; D016480:Helicobacter pylori / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications* / Q000601:surgery*; D012189:Retrospective Studies; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G